Application of pirfenidone or CXCR4 inhibitor in preparation of medicine for improving radiotherapy sensitivity of metastatic liver cancer
By using pirfenidone or CXCR4 inhibitors to prevent hepatic stellate cell activation and CXCL14-CXCR4 signaling axis, the problem of immune escape in radiotherapy for metastatic liver cancer was solved, significantly improved the efficacy of radiotherapy and enhanced the metastatic liver cancer therapeutic effect.
Patent Information
- Application Number
- CN202411327543.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-23
- Publication Date
- 2024-11-29
AI Technical Summary
The radiation therapy of metastatic liver cancer is poor, mainly due to the immunosuppressive reprogramming of macrophages caused by the activation of hepatic stellate cells, resulting in immune escape and anti-therapeutic efficacy.
使用吡非尼酮或CXCR4抑制剂,阻止肝星状细胞的活化和CXCL14-CXCR4信号轴的阻断,恢复CD8+T细胞的抗肿瘤免疫,增强放射治疗的疗效。
Effectively prevent the immunosuppressive reprogramming of macrophages, restore the anti-tumor immune response, significantly improve the efficacy of radiation therapy, and have an important impact on the treatment of metastatic liver cancer.
Smart Images

Figure CN119033780A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to an application of pirfenidone or a CXCR4 inhibitor in the preparation of a drug for improving the radiotherapy sensitivity of metastatic liver cancer. Background Art
[0002] The liver is one of the most common metastatic organs of malignant tumors, and liver metastasis is the main obstacle to the long-term survival of patients with gastrointestinal tumors. Although immunotherapy, chemoradiotherapy, targeted therapy and surgical techniques have made great progress in recent years, the high heterogeneity and immunosuppressive properties of liver metastasis are still a treatment dilemma for patients with liver metastasis, which makes it urgent to explore the local characteristics of liver metastasis and conduct extensive research on potential treatment strategies.
[0003] Radiotherapy is one of the most important treatments for metastatic liver cancer, and the most commonly used radiotherapy for metastatic liver cancer is stereotactic body radiotherapy (SBRT). Radiotherapy can not only directly induce DNA breakage or induce the production of reactive oxygen species to kill cancer cells through high-energy radiation, but also stimulate the body's anti-tumor immune response. However, this therapeutic effect will be partially offset by immune escape and tissue matrix activation, which is why immune "cold" tumors lack clinical benefits and remote effects.
[0004] Tumor-associated macrophages (TAMs) are drivers of immunosuppression and cancer progression. Currently, therapeutic strategies targeting macrophages include reducing the number of TAMs and reversing the tumor-promoting phenotype of TAMs. Among them, reducing the number of TAMs can be divided into two main pathways: one is to inhibit the CSF-1 / CSF-1R signaling axis to deplete TAMs in the microenvironment; the other is to inhibit CCL2-CCR2 signaling to block the recruitment of monocytes. However, complete depletion of TAMs has the following problems: (1) The potential immunostimulatory effect of macrophages as major phagocytes and professional antigen-presenting cells is lost. (2) Ideally, macrophages not related to cancer should not be affected, such as tissue-retaining macrophages, which help maintain organ homeostasis. (3) Long-term tumor control requires the active participation of the adaptive immune system, and the use of a single drug may be difficult to achieve long-term control of cancer. Therefore, reversing the tumor-promoting phenotype of TAMs is one of the more attractive therapeutic strategies currently.
[0005] During radiotherapy for metastatic liver cancer, some TAMs are reprogrammed into an immunosuppressive phenotype characterized by high expression of PD-L1, which inhibits the body's anti-tumor immune response and causes immune escape, thereby offsetting part of the therapeutic effect of radiotherapy and resulting in limited effectiveness of radiotherapy.
[0006] In view of this, if the immunosuppressive reprogramming of TAMs can be inhibited and reversed, and anti-tumor immunity can be restored, the efficacy of radiotherapy can be effectively enhanced, and the radiosensitization effect of metastatic liver cancer can be achieved, which is of great significance for the treatment of metastatic liver cancer. Summary of the invention
[0007] In view of the technical problems existing in the background technology, the present application provides the use of pirfenidone or CXCR4 inhibitor in the preparation of a drug for improving the radiotherapy sensitivity of metastatic liver cancer, aiming to solve the technical problem of poor radiotherapy effect of metastatic liver cancer.
[0008] The embodiments of the present application provide the use of pirfenidone or a CXCR4 inhibitor in the preparation of a drug for improving the radiotherapy sensitivity of metastatic liver cancer.
[0009] In the technical solution of the embodiment of the present application, pirfenidone or CXCR4 inhibitor can effectively prevent the immunosuppressive reprogramming of TAMs, thereby restoring CD8 + The anti-tumor immunity of T cells, using pirfenidone or CXCR4 inhibitors to prepare corresponding drugs can improve the efficacy of radiotherapy and achieve radiosensitization of metastatic liver cancer.
[0010] In some embodiments, the pirfenidone is used to target and inhibit the activation of hepatic stellate cells.
[0011] In the technical solution of the embodiment of the present application, radiotherapy promotes the activation of hepatic stellate cells (HSCs), and the activation of HSCs will cause TAMs to be reprogrammed into an immunosuppressive phenotype characterized by high expression of PD-L1, inhibiting the body's anti-tumor immune response and weakening the effect of radiotherapy. Pirfenidone can target and inhibit the activation of HSCs, thereby preventing the immunosuppressive reprogramming of TAMs and restoring CD8 + T cell anti-tumor immunity achieves radiotherapy sensitization effect.
[0012] In some embodiments, the CXCR4 inhibitor is used to target and block the CXCL14-CXCR4 signaling axis of hepatic stellate cell activation.
[0013] In the technical solution of the embodiment of the present application, activated hepatic stellate cells release CXCL14, which acts on the membrane receptor CXCR4 of liver macrophages, thereby reprogramming them into an immunosuppressive phenotype characterized by high expression of PD-L1. CXCR4 inhibitors can also prevent the immunosuppressive reprogramming of TAMs by blocking the CXCL14-CXCR4 signaling axis and restore CD8 + T cell anti-tumor immunity achieves radiotherapy sensitization effect.
[0014] In some embodiments, the drug for improving the radiotherapy sensitivity of metastatic liver cancer comprises an active ingredient and a pharmaceutically acceptable carrier and / or excipient; the active ingredient includes pirfenidone and / or a CXCR4 inhibitor.
[0015] In some embodiments, the CXCR4 inhibitor is plerixafor.
[0016] In some embodiments, the administration of the drug for improving the radiosensitivity of metastatic liver cancer includes oral administration or injection administration.
[0017] In some embodiments, in the drug for improving the radiosensitivity of metastatic liver cancer, the dosage of the active ingredient pirfenidone is 250-350 mg / kg ip.
[0018] In some embodiments, in the drug for improving the radiosensitivity of metastatic liver cancer, the dosage of the active ingredient plerixafor is 4-6 mg / kg ip.
[0019] In some embodiments, the metastatic liver cancer comprises liver metastases from digestive tract cancer.
[0020] In some embodiments, the digestive tract cancer comprises colorectal cancer or pancreatic cancer.
[0021] The above description is only an overview of the technical solution of the present application. In order to more clearly understand the technical means of the present application, it can be implemented in accordance with the contents of the specification. In order to make the above and other purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are listed below. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the technical solution of the present application, the following is a brief introduction to the drawings used in the present application. Obviously, the drawings described below are only some embodiments of the present application, and for ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0023] Figure 1 The results of qRT-PCR after treatment of mouse primary HSCs;
[0024] Figure 2 The diagram is a dosing pattern diagram for non-tumor-bearing mice;
[0025] Figure 3 The results of tissue immunofluorescence staining analysis were analyzed;
[0026] Figure 4 PD-L1 in the liver tissue of each group of mice + Comparison chart of the number and proportion of macrophages;
[0027] Figure 5 This is a diagram of the drug administration pattern for mice in the colorectal cancer spleen and liver metastasis model;
[0028] Figure 6 This is the gross appearance of liver metastases in mice with a colorectal cancer liver metastasis model via spleen;
[0029] Figure 7 This is a statistical diagram of the number of tumor nodules on the liver surface of mice in the colorectal cancer liver metastasis model;
[0030] Figure 8 This is a statistical chart of the liver-to-body weight ratio of mice in the colorectal cancer liver metastasis model;
[0031] Fig. 9 The proportion of various types of cells in the liver metastasis tissue of mice with colorectal cancer liver metastasis model via spleen;
[0032] Fig.10 This is a survival analysis diagram of mice in the colorectal cancer spleen and liver metastasis model;
[0033] Fig.11 This is a diagram of the drug administration pattern for mice in the pancreatic cancer metastasis model via spleen and liver;
[0034] Fig.12 This is the gross view of liver metastases in mice with pancreatic cancer metastasis via spleen and liver.
[0035] Fig.13 This is a statistical diagram of the number of tumor nodules on the liver surface of mice in the pancreatic cancer liver metastasis model via spleen;
[0036] Fig.14 This is a statistical chart of the liver-to-body weight ratio of mice in the pancreatic cancer liver metastasis model;
[0037] Fig.15 The proportion of various types of cells in the liver metastasis tissue of mice with pancreatic cancer metastasis through spleen and liver model;
[0038] Fig.16 This is a survival analysis of mice in the pancreatic cancer spleen and liver metastasis model. DETAILED DESCRIPTION
[0039] The following embodiments of the technical solution of the present application are described in detail in conjunction with the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of the present application, and are therefore only used as examples, and cannot be used to limit the scope of protection of the present application.
[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by technicians in the technical field to which this application belongs; the terms used herein are only for the purpose of describing specific embodiments and are not intended to limit this application; the terms "including" and "having" in the specification and claims of this application and the above-mentioned figure descriptions and any variations thereof are intended to cover non-exclusive inclusions.
[0041] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.
[0042] In the description of the embodiments of the present application, the term "and / or" is only a description of the association relationship of the associated objects, indicating that there may be three relationships. For example, A and / or B can represent: A exists alone, A and B exist at the same time, and B exists alone. In addition, the character " / " in this article generally indicates that the associated objects before and after are in an "or" relationship.
[0043] During radiotherapy for metastatic liver cancer, some TAMs are reprogrammed into an immunosuppressive phenotype characterized by high expression of PD-L1, which inhibits the body's anti-tumor immune response and causes immune escape, thereby offsetting part of the therapeutic effect of radiotherapy and resulting in limited effectiveness of radiotherapy.
[0044] Through research, this application found that the occurrence and development of metastatic liver cancer is closely related to macrophage immune remodeling driven by hepatic stellate cells (HSCs) activation, and radiotherapy for metastatic liver cancer will enhance the activation level of HSCs. Activated HSCs will release CXCL14, which acts on the dry macrophage membrane receptor CXCR4 and reprograms them into an immunosuppressive phenotype characterized by high expression of PD-L1, thereby causing immune escape. Therefore, on the one hand, radiotherapy for metastatic liver cancer can induce anti-tumor immunity by directly killing cancer cells, but on the other hand, the activation of HSCs caused by radiotherapy will inhibit anti-tumor immunity. After the two effects are partially offset, the radiotherapy effect is poor.
[0045] Based on the above-mentioned mechanism of action discovered in the present application, the present application provides the use of pirfenidone or CXCR4 inhibitor in the preparation of a drug for improving the radiotherapy sensitivity of metastatic liver cancer, which provides a new idea for the treatment of metastatic liver cancer by breaking the HSCs-mediated immune tolerance from the source.
[0046] On the one hand, pirfenidone (PFD) can be used to target and inhibit the activation of HSCs; on the other hand, CXCR4 inhibitors can be used to block the CXCL14-CXCR4 signaling axis. Both approaches can prevent the immunosuppressive reprogramming of TAMs and restore CD8 + The anti-tumor immunity of T cells enables radiotherapy to fully exert its role in inducing anti-tumor immunity and achieve the radiotherapy sensitization effect.
[0047] Furthermore, in some embodiments, the drug for improving the radiotherapy sensitivity of metastatic liver cancer comprises an active ingredient and a pharmaceutically acceptable carrier and / or excipient; the active ingredient includes pirfenidone and / or a CXCR4 inhibitor.
[0048] Further, in some embodiments, the CXCR4 inhibitor is plerixafor.
[0049] Furthermore, in some embodiments, the administration of the drug for improving the radiosensitivity of metastatic liver cancer includes oral administration or injection administration.
[0050] Furthermore, in some embodiments, in the drug for improving the radiosensitivity of metastatic liver cancer, the dosage of the active ingredient pirfenidone is 250-350 mg / kg ip.
[0051] Furthermore, in some embodiments, in the drug for improving the radiosensitivity of metastatic liver cancer, the dosage of the active ingredient plerixafor is 4-6 mg / kg ip.
[0052] Further, in some embodiments, the metastatic liver cancer includes liver metastases of digestive tract cancer.
[0053] Further, in some embodiments, the digestive tract cancer includes colorectal cancer or pancreatic cancer.
[0054] Some specific embodiments are listed below. It should be noted that the embodiments described below are exemplary and are only used to explain the present application, and should not be construed as limiting the present application. If specific techniques or conditions are not specified in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used without specifying the manufacturer are all conventional products that can be obtained commercially.
[0055] In some specific examples of the present application, Plerixafor (also known as AMD3100) is selected as a CXCR4 inhibitor, and the specific application effects of Pirfenidone (PFD) and Plerixafor are studied. The following is a detailed description:
[0056] First, radiotherapy promotes HSCs activation, while PFD can inhibit HSCs activation, and Plerixafor can block the CXCL14-CXCR4 signaling axis. Both can reduce PD-L1 after radiotherapy. + The percentage of macrophages.
[0057] Mouse primary HSCs were randomly divided into Ctrl group (control group), PFD group, IR group and IR+PFD group. The Ctrl group was not treated with any treatment, the PFD group was treated with 1mM PFD, the IR group was treated with 8Gy ionizing radiation, and the IR+PFD group was treated with 8Gy ionizing radiation and 1mM PFD. RNA was extracted for qRT-PCR detection 48 hours after treatment. The results are shown in Figure 1 shown.
[0058] Depend on Figure 1 It can be seen that compared with the control group, after radiotherapy, the expression of HSCs activation markers αSMA (encoding gene Aata2) and CXCL14 was upregulated, and the addition of PFD could reverse this phenomenon.
[0059] Further in vivo verification: 8-week-old C57BL / 6 mice were fed adaptively in an SPF animal room for one week and then randomly divided into 5 groups: Ctrl group, 8 Gy group, 8 × 3 Gy group, 8 × 3 Gy + PFD group, and 8 × 3 Gy + Plerixafor group. The drug administration mode was as follows: Figure 2 shown.
[0060] Tissue immunofluorescence staining analysis was performed on the Ctrl group, 8Gy group, 8×3Gy group, and 8×3Gy+PFD group. Figure 3 shown. Figure 3 In the figure, red indicates αSMA, blue indicates DAPI, and the scale bar is 100 μm. Figure 3 It can be seen that in the absence of tumor, the dose of radiotherapy is positively correlated with the activation level of HSCs, and PFD can interfere with radiotherapy-mediated HSCs activation.
[0061] Flow cytometry was used to analyze the expression of PD-L1 in the liver tissues of the above five groups of mice. + The number and proportion of macrophages were tested, and the results were as follows Figure 4 shown.
[0062] Depend on Figure 4 It can be seen that PD-L1 in the liver immune microenvironment of mice in the 8x 3Gy group + The number of macrophages accounted for the highest proportion, which was 3.63 times that of the untreated group and 1.90 times that of the 8Gy group, indicating that the dose of radiotherapy is related to PD-L1 +The combination of radiotherapy with PFD or Plerixafor can effectively reduce the expression of PD-L1 after radiotherapy. + The number of macrophages.
[0063] Therefore, radiotherapy promotes the activation of HSCs and produces more PD-L1 + Macrophages inhibit anti-tumor immunity, and the higher the dose of radiotherapy, the more PD-L1 is produced + The more macrophages there are, the negative effects will greatly offset the anti-tumor immunity induced by radiotherapy, resulting in unsatisfactory radiotherapy effects. The combination of PFD or Plerixafor as a radiosensitizer with radiotherapy can effectively reduce PD-L1 + The number of macrophages can fully exert the anti-tumor immune effect induced by radiotherapy, improve the efficacy of radiotherapy, and achieve radiosensitization of metastatic liver cancer.
[0064] 2. Using PFD or Plerixafor as a radiosensitizer in combination with radiotherapy can effectively inhibit colorectal cancer liver metastasis.
[0065] A mouse model of colorectal cancer metastasis via spleen and liver was established and randomly divided into 6 groups: Ctrl group, IR group, Plerixafor group, PFD group, Plerixafor+IR group, and PFD+IR group. The drug administration mode was as follows: Figure 5 shown.
[0066] The liver metastases of mice in each group were detected and analyzed. Figure 6-7 As shown. Among them, Figure 6 This is the gross appearance of liver metastasis. Figure 7 The ratio of liver to body weight of each group of mice was statistically analyzed. Figure 8 shown.
[0067] Depend on Figure 6-8 It can be seen that the therapeutic effect of 8Gy radiotherapy alone on liver metastases is limited, while the combined use of PFD or Plerixafor can significantly inhibit the growth of liver metastases. The data of each group were statistically different from those of the control group, proving that breaking the HSCs-mediated immune escape is the key to treating colorectal cancer liver metastases.
[0068] The liver metastasis tissues of each group of mice were further analyzed by flow cytometry. Fig. 9 As shown. Fig. 9 It can be seen that: on the one hand, compared with the control group, the PD-L1 +There was no statistical difference in the number of macrophages. Although the monotherapy group with PFD or Plerixafor could reduce the expression of PD-L1 + The number of macrophages was significantly reduced in the IR and PFD or Plerixafor combination treatment groups. + It can be seen that although radiotherapy can induce anti-tumor immune effects by directly killing cancer cells, its activation of HSCs to promote the high expression of PD-L1 in macrophages partially offsets the corresponding anti-tumor immune effects, resulting in the increase of PD-L1. + There was no statistical difference in the number of macrophages, and the radiotherapy effect was poor. The combined use of PFD or Plerixafor and radiotherapy is not a simple superposition of effects, but rather the use of PFD or Plerixafor to target the high expression of PD-L1 in macrophages, thereby specifically eliminating the negative effects of radiotherapy and giving full play to the efficacy of radiotherapy, thereby achieving a radiosensitization effect.
[0069] On the other hand, compared with the control group, although the other groups were able to increase CD8 + However, the effect of PFD or Plerixafor combined with radiotherapy was significantly more significant, and PFD was superior to Plerixafor.
[0070] The Kaplan-Meier method was further used to analyze the survival of mice in each group. Fig.10 As shown. Fig.10 It can be seen that compared with the control group, each group can improve the survival benefits of mice with liver metastasis, among which the combined treatment group can significantly prolong the survival time of mice by more than 20 days.
[0071] Therefore, for mice with colorectal cancer splenic-liver metastasis model, using PFD or Plerixafor as a radiosensitizer in combination with radiotherapy can target and destroy immune escape, thereby improving the efficacy of radiotherapy and curbing the formation and development of colorectal cancer liver metastasis.
[0072] 3. Using PFD or Plerixafor as a radiosensitizer in combination with radiotherapy can effectively inhibit pancreatic cancer liver metastasis.
[0073] A mouse pancreatic cancer metastasis model via spleen and liver was established and randomly divided into 6 groups: Ctrl group, IR group, Plerixafor group, PFD group, Plerixafor+IR group, and PFD+IR group. The drug administration mode was as follows: Fig.11 shown.
[0074] The liver metastases of mice in each group were detected and analyzed. Figure 12-13 As shown. Among them, Fig.12 This is the gross appearance of liver metastasis. Fig.13 The ratio of liver to body weight of each group of mice was statistically analyzed. Fig.14 The liver metastasis tissues of each group of mice were analyzed by flow cytometry. The results are shown in Fig.15 The Kaplan-Meier method was further used to analyze the survival of mice in each group. Fig.16 shown.
[0075] according to Figure 12-16 It can be seen that in the mouse pancreatic cancer spleen-liver metastasis model, similar rules were shown as in the mouse colorectal cancer spleen-liver metastasis model, proving that the use of PFD or Plerixafor as a radiotherapy sensitizer in combination with radiotherapy can also curb the formation and development of pancreatic cancer liver metastasis, indicating that the application provided in this application has a wide range of applicability and can be applied to different types of metastatic liver cancer.
[0076] In summary, the present application provides the use of pirfenidone or CXCR4 inhibitors in the preparation of drugs for improving the radiotherapy sensitivity of metastatic liver cancer, which belongs to the field of biomedicine. Among them, pirfenidone can target and inhibit the activation of HSCs, thereby preventing TAMs from reprogramming to an immunosuppressive phenotype characterized by high expression of PD-L1, preventing the immune escape caused by TAMs reprogramming from affecting the effect of radiotherapy, thereby restoring CD8 + The anti-tumor immunity of T cells can achieve the radiosensitization effect of metastatic liver cancer. CXCR4 inhibitors can also prevent the immunosuppressive reprogramming of TAMs by targeting and blocking the CXCL14-CXCR4 signaling axis activated by HSCs, thereby achieving the radiosensitization effect on metastatic liver cancer. This application uses pirfenidone or CXCR4 inhibitors to prepare drugs that improve the radiosensitivity of metastatic liver cancer, effectively enhancing the efficacy of radiotherapy, which is of great significance for the treatment of metastatic liver cancer.
[0077] It should be noted that the present application is not limited to the above-mentioned embodiments. The above-mentioned embodiments are only examples, and the embodiments having the same structure as the technical idea and exerting the same effect within the scope of the technical solution of the present application are all included in the technical scope of the present application. In addition, without departing from the scope of the main purpose of the present application, various modifications that can be thought of by those skilled in the art to the embodiments and other methods of combining some of the constituent elements in the embodiments are also included in the scope of the present application.
Claims
1. Use of pirfenidone or CXCR4 inhibitors in the preparation of drugs for improving the radiosensitivity of metastatic liver cancer.
2. The use of pirfenidone or a CXCR4 inhibitor according to claim 1 in the preparation of a drug for improving the radiosensitivity of metastatic liver cancer, characterized in that: The pirfenidone is used for targeted inhibition of the activation of hepatic stellate cells.
3. Use of pirfenidone or a CXCR4 inhibitor according to claim 1 in the preparation of a drug for improving the radiosensitivity of metastatic liver cancer, characterized in that: The CXCR4 inhibitor is used for targeted blocking of the CXCL14-CXCR4 signaling axis of hepatic stellate cell activation.
4. Use of pirfenidone or a CXCR4 inhibitor according to claim 1 in the preparation of a drug for improving the radiosensitivity of metastatic liver cancer, characterized in that: The drug for improving the radiotherapy sensitivity of metastatic liver cancer comprises an effective ingredient and a pharmaceutically acceptable carrier and / or excipient; the effective ingredient includes pirfenidone and / or a CXCR4 inhibitor.
5. Use of pirfenidone or a CXCR4 inhibitor according to claim 4 in the preparation of a drug for improving the radiosensitivity of metastatic liver cancer, characterized in that: The CXCR4 inhibitor is plerixafor.
6. Use of pirfenidone or a CXCR4 inhibitor according to claim 4 in the preparation of a drug for improving the radiosensitivity of metastatic liver cancer, characterized in that: The administration method of the drug for improving the radiotherapy sensitivity of metastatic liver cancer includes oral administration or injection administration.
7. Use of pirfenidone or a CXCR4 inhibitor according to claim 6 in the preparation of a drug for improving the radiosensitivity of metastatic liver cancer, characterized in that: In the drug for improving the radiotherapy sensitivity of metastatic liver cancer, the dosage of the active ingredient pirfenidone is 250-350 mg / kg ip.
8. Use of pirfenidone or a CXCR4 inhibitor according to claim 1 in the preparation of a drug for improving the radiosensitivity of metastatic liver cancer, characterized in that: In the drug for improving the radiotherapy sensitivity of metastatic liver cancer, the dosage of the active ingredient plerixafor is 4-6 mg / kg ip.
9. Use of pirfenidone or a CXCR4 inhibitor according to claim 1 in the preparation of a drug for improving the radiosensitivity of metastatic liver cancer, characterized in that: The metastatic liver cancer includes liver metastasis of digestive tract cancer.
10. Use of pirfenidone or a CXCR4 inhibitor according to claim 1 in the preparation of a drug for improving the radiosensitivity of metastatic liver cancer, characterized in that: The digestive tract cancer includes colorectal cancer or pancreatic cancer.
